Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager . Agreement also gives Novartis ...
(“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the ...
CaseBioscience® today announced its participation in a multidisciplinary team led by Likarda that has been awarded up to $7.3 ...
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its ...
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting ...
Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation ...
Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for ...
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...
Clear Scientific, Inc. today announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule ...
Participants were assigned to one of three groups: lorundrostat 50 mg once daily; lorundrostat 50 mg once daily with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results